Platinum Priority – Brief CorrespondenceEditorial by Alexander Laird, David. J. Harrison and Grant D. Stewart on pp. 21–22 of this issueA Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition
References (10)
- et al.
Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability
Eur Urol
(2009) - et al.
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
Cancer Treat Rev
(2008) - et al.
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score
J Urol
(2002) - et al.
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
Cancer Treat Rev
(2014) Renal-cell carcinoma—molecular pathways and therapies
N Engl J Med
(2007)
Cited by (24)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
2018, Clinical Genitourinary CancerCitation Excerpt :Although these ccRCC driver mutations are typically subclonal, a parallel convergent evolution of subclones is often present.13 On a transcriptomic level, other groups have demonstrated the existence of prognostic molecular subtypes of ccRCC in the postnephrectomy setting, based on cluster analysis of whole genome mRNA expression data.14-17 Brooks et al18 have proposed a 34-gene classifier, Clearcode34, which classifies tumors into a good-risk (ccA) or poor-risk (ccB) group.
Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study
2017, Clinical Genitourinary CancerCitation Excerpt :It is known that RCC is originated by multiple clones progressing simultaneously that develop different characteristics to promote growth and metastases. Although efforts are currently under way to create prognostic panels that analyze multiple genes to identify genetic signatures associated with RCC prognosis and therapeutic possibilities,32,33 these panels are still no better than currently established clinical prognostic factors and must be validated in prospective studies before they can be applied in clinical practice. In our study, stages III to IV as well as Fuhrman nuclear grades 3 and 4 were closely associated with shorter OS, DSS, and PFS and were shown in the Cox analysis to be the only independent variables associated with a higher risk of death or progression.
Postoperative Surveillance for Renal Cell Carcinoma
2017, Urologic Clinics of North AmericaCitation Excerpt :Indeed, a 16-gene assay36 and 34-gene assay37 developed for clear cell RCC show improvement in prognostication over clinical indicators. Among a subset of patients, a multigene panel generated to distinguish prognostic subtypes of clear cell RCC was found to be associated with radiographic response to tyrosine kinase inhibitor therapy and survival.38 Although these personalized tools show promise in reducing costs and radiation exposure by focusing surveillance to those at greatest risk, disadvantages of access and cost from implementing widespread genetic testing will be difficult to offset.
Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma
2015, Urologic Oncology: Seminars and Original InvestigationsProfilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma
2015, Human PathologyCitation Excerpt :Recent evidence has shown the presence of molecular subtypes of ccRCC of distinct prognosis and differential response to targeted therapy. Although these subtypes are indistinguishable by morphology, the use of molecular markers can help to stratify these subtypes with significant clinical implications [24-28]. Our results are in line with recent literature showing that Pfn1 affects cell migration and invasion and tumor aggressive behavior [29].
Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective
2015, Surgical Pathology ClinicsCitation Excerpt :An external validation set confirmed this association and this germline alteration may be incorporated in future prognostic tools or used to plan further adjuvant clinical trials.23 More elaborate approaches to assess recurrence risk, such as gene expression signatures, have been reported, with 3 models already available,24–26 including a 16-gene signature, recently externally validated in stage I–III ccRCC.27 These tools, however, are not currently available in clinical practice, and, given the lack of approved adjuvant therapy, the relevance of these signatures is limited to the ability of providing additional prognostic information without direct influence on therapeutic or monitoring guidelines.